1. A polymer-enhanced proppant transport fluid, comprising:
a suspension fluid comprising a crosslinked synthetic polymer gel formulation, and
a plurality of proppant particles.
2. The fluid of claim 1, wherein the crosslinked synthetic polymer gel formulation comprises:
at least one synthetic base polymer, and
a crosslinking agent, wherein the crosslinking agent comprises a dialdehyde or a dual crosslinker system.
3. The fluid of claim 2, wherein the dual crosslinker system comprising a dialdehyde and an organometallic reagent.
4. The fluid of claim 2, wherein the crosslinked synthetic polymer gel formulation comprises a second base polymer.
5. The fluid of claim 4, wherein the second base polymer is a synthetic base polymer.
6. The fluid of claim 5, wherein the at least one synthetic base polymer and the second base polymer are crosslinked.
7. The fluid of claim 6, wherein the crosslinking is performed by a crosslinking agent.
8. The fluid of claim 1, wherein the crosslinked synthetic polymer gel formulation further comprises a hydrophobically associating base polymer with a tunable surfactant.
9. The fluid of claim 1, wherein the crosslinked synthetic polymer gel formulation further comprises a superabsorbent polymer with a water soluble polymer.
10. A method of improving production from an oil or gas well, comprising:
providing a formulation comprising a crosslinked synthetic polymer gel formulation, and
delivering the formulation into the oil or gas well, whereby the formulation improves production from the well.
11. A method of water blocking or water shutoff in an oil or gas well, comprising:
providing a formulation comprising a crosslinked synthetic polymer gel formulation, and
delivering the formulation into the oil or gas well, whereby the formulation provides water blocking or water shutoff in the well.
12. A method of enhancing oil recovery from an oil source, comprising:
providing a formulation comprising a crosslinked synthetic polymer gel formulation, and
delivering the formulation into the oil source, whereby the formulation enhances oil recover from the oil source.
13. A method of treating a petroleum-containing formation to reduce sand production, comprising:
providing a formulation comprising a crosslinked synthetic polymer gel formulation, and
delivering the formulation into the petroleum-containing formation, whereby the formulation reduces sand production in the formation.
14. A method of displacing fluid from a wellbore by viscous plug flow, comprising:
providing a formulation comprising a crosslinked synthetic polymer gel formulation, and
delivering the formulation into wellbore, whereby the formulation forms a viscous plug in the wellbore, thereby displacing fluid therefrom.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for treating a disease state in mammals characterized by abnormally low levels of inflammatory agents by up-regulating indigenous in vivo levels of an inflammatory agent comprising:
a. contacting the mammalian cells with an inflammatory regulator, comprising at least 2.8 mg pyruvate, or a pyruvate precursor or salt thereof, \u03b1-keto-isovaleric acid or a precursor thereof and mixtures thereof
b. wherein said inflammatory agents are selected from the group consisting of elastase, white blood cells, tumor necrosis factor-\u03b1 and cytokines selected from the group consisting of interleukin-6, interleukin-8, interleukin-10, interleukin-17, and interleukin-23, and;
c. wherein the disease state is selected from the group consisting of pulmonary and upper respiratory diseases, Alzheimer’s disease, diabetes, and nicotine addiction.
2. The method of claim 1 wherein the pulmonary and upper respiratory disease is selected from the group consisting of infected lungs and infected sinuses, bronchial asthma, acute bronchitis, allergic rhinitis, sinusitis and diseases caused by organic dust, irritant gases, air pollution and chemicals.
3. The method of claim 2 wherein the pyruvate and its’ salts are selected from the group consisting of pyruvic acid, lithium pyruvate, sodium pyruvate, potassium pyruvate, magnesium pyruvate, calcium pyruvate, zinc pyruvate, manganese pyruvate, aluminum pyruvate, ammonium pyruvate, and mixtures thereof.
4. The method of claim 3 wherein the pyruvate precursors are selected from the group consisting of pyruvyl-glycine, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvamide, salts of pyruvic acid, and mixtures thereof.
5. The method of claim 4 wherein the dosage of the inflammatory regulator ranges from about 2.8 mg to about 1.0 gram.
6. The method of claim 5 wherein the disease state is an infected disease state caused by a bacterial, viral, or fungal infection.
7. The method of claim 6 further comprising contacting the mammalian cells with a therapeutic agent.
8. The method according to claim 6 wherein the therapeutic agent is selected from the group consisting of anti-bacterial agents, anti-viral agents, anti-fungals, anti-tumor agents, anti-histamines, proteins, enzymes, hormones, non-steroidal anti-inflammatory agents, cytokines, steroids, nicotine, and insulin.
9. The method of claim 8 wherein the therapeutic agent is selected from the group consisting of insulin.
10. The method of claim 8 wherein the therapeutic agent is selected from the group consisting of nicotine.
11. The method of claim 8 wherein the therapeutic agent is a steroid selected from the group consisting of fluticasone, (Flonase\xae), budesonide (Rhinocort\xae) beclomethasone, mometasone, flunisolide, triamcinolone and mixtures thereof.
12. The method of claim 8, wherein the therapeutic agent is an anti-viral agent selected from the group consisting of acyclovir, foscarnet sodium, ribavirin, vidarabine, ganciclovir sodium, Ribavirim, zidovudine, phenol, amantadine hydrochloride, and interferon \u03b1-n3, interferon \u03b1-2a, and oseltamivir.
13. The method of claim 12 wherein the anti-viral agent is selected from the group consisting of acyclovir, foscarnet sodium, ribavirin, vidarabine, and ganciclovir sodium.
14. The method of claim 8, wherein the therapeutic agent is an anti-biotic agent selected from the group consisting of actinomycins, glutarimide antibiotics, sarkomycin, fumagillin, streptonigrin, Mupericin, tenuazonic acid, actinogan, peptinogan, and the anthracyclic antibiotics.
15. The method of claim 8, wherein the therapeutic agent is an antihistamine selected from the group consisting of pseudoephedrine, loratadine, fexofenadine, diphenhydramine, famodidine, ranitidine, citirazine, and other H1- and H2-antagonists.
16. The method of claim 12 wherein the anti-viral agent is present in an amount of from about 0.01% to about 50% by weight.
17. The method of claim 8, wherein the therapeutic agent is a protein for the treatment of Alzeheimers’ disease
18. The method of claim 17, wherein the protein for the treatment of Alzeheimers’ disease is insulin.
19. The method of claim 8, wherein the therapeutic agent is administered prior to delivery of the inflammatory regulator.
20. The method of claim 8, wherein the therapeutic agent is administered concomitantly with delivery of the inflammatory regulator.
21. The method of claim 8, wherein the therapeutic agent is administered after delivery of the inflammatory regulator.
22. A method for treating a pulmonary and upper respiratory disease state by up-regulating abnormally low levels of inflammatory agents comprising:
a. contacting the mammalian cells with an inflammatory regulator, comprising at least 2.8 mg pyruvate, or a pyruvate precursor or salt thereof, \u03b1-keto-isovaleric acid or a precursor thereof and mixtures thereof
b. wherein said inflammatory agents are selected from the group consisting of elastase, white blood cells, tumor necrosis factor-\u03b1 and cytokines selected from the group consisting of interleukin-6, interleukin-8, interleukin-10, interleukin-17, and interleukin-23, and;
c. wherein the disease state is selected from the group consisting of allergic rhinitis, sinusitis, Alzheimer’s disease, diabetes, nicotine addiction, infected lungs and infected sinuses, bronchial asthma, and acute bronchitis.
23. A method for treating an abnormal pulmonary and upper respiratory condition by up-regulating abnormally low levels of inflammatory agents comprising the administration of an inflammatory regulator, comprising at least 2.8 mg pyruvate, or a pyruvate precursor or salt thereof, \u03b1-keto-isovaleric acid or a precursor thereof and mixtures thereof;
b. wherein said inflammatory agents are selected from the group consisting of elastase, white blood cells, tumor necrosis factor-\u03b1 and cytokines selected from the group consisting of interleukin-6, interleukin-8, interleukin-10, interleukin-17, and interleukin-23, and;
c. wherein the respiratory condition is selected from the group consisting of sinus irritation and congestion, lung irritation and congestion and snoring.